Phase 2 Clinical Trial For IPF Patients With Chronic Cough

Marta Ribeiro avatar

by Marta Ribeiro |

Share this article:

Share article via email

pf_phase 2

Afferent Pharmaceuticals, a biotechnology company dedicated to therapies for neurogenic disorders, recently announced the beginning of a Phase 2 clinical trial to assess its candidate product AF-219 for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF).

Neurogenic disorders are conditions associated with the central nervous system and affect millions of individuals. They occur when certain nerves become hyper-sensitized due to distress, infection, inflammation or tissue injury; this sensitization can lead to chronic and debilitating symptoms.

Read more about it: http://bit.ly/1IRoP5t

Print This Page

About the Author

Marta Ribeiro avatar
Marta Ribeiro Marta graduated from Universidade Fernando Pessoa in Porto with a degree in Communication Sciences and a Masters degree in New Communication Technologies. She has experience in social media, worked with several media channels, and has also worked as a freelance photographer and a graphic artist for almost 10 years.

Tags

chronic cough, Idiopathic pulmonary fibrosis (IPF), IPF, IPF clinical trials, pulmonary fibrosis

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums

Recent Posts


Recommended reading